ClinicalTrials.gg
CompletedNCT01469377Updated May 1, 2018Results posted

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

A Phase 2 interventional study of Placebo and Cariprazine in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 72 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-05-01.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
819
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.

Enrollment
7th of 53
819 · median 442
Started
2011
with 6 others
Phase 2
12 of 53
1 open now
Registered
19th of 53
by date

Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 7th largest by enrollment, is one of 7 that started in 2011, is one of 12 in phase 2, and was the 19th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Depressive Disorder, Major by AbbVie, or all of them as a file.
02

Study summary

An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone. This clinical study compared cariprazine + ADT with placebo + ADT in outpatients with a diagnosis of MDD and an inadequate response to ADT. The study consisted of approximately 2 weeks of screening and washout followed by 8 weeks of double-blind treatment followed by a 1 week safety follow-up.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major depressive disorder
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients 18 to 65 years of age, inclusive.
  • Currently meet the , Fourth Edition, Text Revision (DSM-IV-TR) criteria for moderate to severe major depressive disorder (MDD).
  • Current major depressive episode of at least 8 weeks and not exceeding 24 months in duration.
  • Ongoing inadequate response to protocol allowed antidepressant therapy (ADT).

Exclusion criteria

Exclusion Criteria:

  • Principal -based diagnosis of an axis I disorder, other than MDD,
  • Women who are pregnant, or planning to become pregnant or breastfeed during the study or not practicing reliable that will continue through out the study.
  • History of meeting DSM-IV-TR criteria for:

    1. Depressive episode with psychotic or catatonic features.
    2. Manic, hypomanic or mixed episode, including bipolar disorder and substance induced manic, hypomanic or mixed episode.
    3. Schizophrenia, schizoaffective, or other psychotic disorder.
    4. Obsessive-compulsive disorder.
    5. Bulimia or anorexia nervosa.
    6. Dementia, amnesic, or other cognitive disorder.
    7. Mental retardation.
  • Participants considered a suicide risk.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
819 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.

    Drug: Placebo

  • Experimental
    Cariprazine 1-2 mg

    Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.

    Drug: Cariprazine

  • Experimental
    Cariprazine 2-4.5 mg

    Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.

    Drug: Cariprazine

Interventions

  • DrugPlacebo

    Placebo was supplied in capsules

  • Cariprazine was supplied in capsules.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8

    The SDS measures an individual's perception of the extent to which his or her emotional symptoms are disrupting his or her functioning in 3 domains, work/school, social life/leisure activities, and family life/home responsibilities. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). Scores of 0 to 3 indicate mild functional impairment, 4 to 6 indicate moderate functional impairment, and 7 to 9 indicate marked functional impairment. The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change score indicates improvement.

    Time frame: Baseline to Week 8

07

Results

Posted May 1, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine 1-2 mgCariprazine 2-4.5 mg
Started269274276
Completed234226210
Not completed354866
Withdrew: Protocol deviation71010
Withdrew: Lost to follow-up325
Withdrew: Withdrawal of consent121415
Withdrew: Adverse event81836
Withdrew: Insufficient therapeutic response340
Withdrew: Other miscellaneous reasons200

Outcome measures

PrimaryChange From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8

The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8
Units on a scalePlaceboCariprazine 1-2 mgCariprazine 2-4.5 mg
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8-12.5 ± 0.5-13.4 ± 0.5-14.6 ± 0.6
Statistical analysis
  • Placebo vs Cariprazine 1-2 mg · Mixed-effect model for repeated measures · p = 0.2404 (p-values were from an mixed-effects model for repeated measures with treatment group, pooled study center, visit, and treatment-group-by-visit interaction as fixed effects and the baseline value and baseline value-by-visit interaction as covariates.) · Least squares mean difference: -0.9 · 95% CI -2.4 to 0.6p-values were adjusted for multiple comparisons using the matched parallel gate-keeping procedure.
  • Placebo vs Cariprazine 2-4.5 mg · Mixed-effect model for repeated measures · p = 0.0114 (p-values were from an mixed-effects model for repeated measures with treatment group, pooled study center, visit, and treatment-group-by-visit interaction as fixed effects and the baseline value and baseline value-by-visit interaction as covariates.) · Least squares mean difference: -2.2 · 95% CI -3.7 to -0.6p-values were adjusted for multiple comparisons using the matched parallel gate-keeping procedure.
SecondaryChange From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8

The SDS measures an individual's perception of the extent to which his or her emotional symptoms are disrupting his or her functioning in 3 domains, work/school, social life/leisure activities, and family life/home responsibilities. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). Scores of 0 to 3 indicate mild functional impairment, 4 to 6 indicate moderate functional impairment, and 7 to 9 indicate marked functional impairment. The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change score indicates improvement.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8
Units on a scalePlaceboCariprazine 1-2 mgCariprazine 2-4.5 mg
Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8-6.6 ± 0.5-7.7 ± 0.5-8.0 ± 0.5
Statistical analysis
  • Placebo vs Cariprazine 1-2 mg · Mixed-effect model for repeated measures · p = 0.2404 (p-values were from an mixed-effects model for repeated measures with treatment group, pooled study center, visit, and treatment-group-by-visit interaction as fixed effects and the baseline value and baseline value-by-visit interaction as covariates.) · Least squares mean difference: -1.1 · 95% CI -2.5 to 0.3p-values were adjusted for multiple comparisons using the matched parallel gate-keeping procedure.
  • Placebo vs Cariprazine 2-4.5 mg · Mixed-effect model for repeated measures · p = 0.1140 (p-values were from an mixed-effects model for repeated measures with treatment group, pooled study center, visit, and treatment-group-by-visit interaction as fixed effects and the baseline value and baseline value-by-visit interaction as covariates.) · Least squares mean difference: -1.4 · 95% CI -2.8 to 0.0p-values were adjusted for multiple comparisons using the matched parallel gate-keeping procedure.

Adverse events

Collected over Adverse Events were collected and recorded from the time the participant signs the informed consent form until 30 days after the last dose of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/266 (0%)1/266 (0.4%)102/266 (38.3%)
Cariprazine 1-2 mg0/273 (0%)0/273 (0%)121/273 (44.3%)
Cariprazine 2-4.5 mg0/273 (0%)3/273 (1.1%)179/273 (65.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboCariprazine 1-2 mgCariprazine 2-4.5 mg
DepressionPsychiatric disorders1/2660/2730/273
Non-cardiac chest painGeneral disorders0/2660/2731/273
AgitationPsychiatric disorders0/2660/2731/273
Panic attackPsychiatric disorders0/2660/2731/273
DyspnoeaRespiratory, thoracic and mediastinal disorders0/2660/2731/273
Myocardial ischemiaCardiac disorders0/2660/2731/273
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboCariprazine 1-2 mgCariprazine 2-4.5 mg
AkathisiaNervous system disorders6/26618/27361/273
InsomniaPsychiatric disorders17/26627/27338/273
HeadacheNervous system disorders36/26624/27324/273
NauseaGastrointestinal disorders13/26619/27335/273
FatigueGeneral disorders11/26618/27327/273
SomnolenceNervous system disorders14/26624/27327/273
RestlessnessPsychiatric disorders7/26622/27323/273
TremorNervous system disorders4/26613/27321/273
DiarrhoeaGastrointestinal disorders14/2668/2738/273
ConstipationGastrointestinal disorders5/2666/27314/273

Baseline characteristics

The Safety Population consisted of all subjects in the Randomized Population who received at least 1 dose of double-blind investigational product.

Age, Continuous
Age, Continuous(years)PlaceboCariprazine 1-2 mgCariprazine 2-4.5 mgTotal
Mean46.4 ± 11.645.5 ± 11.945.1 ± 11.445.7 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCariprazine 1-2 mgCariprazine 2-4.5 mgTotal
Female190187201578
Male768672234
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboCariprazine 1-2 mgCariprazine 2-4.5 mgTotal
White230234242706
All other races363931106
Black or African American32312487
Asian1449
American Indian or Alaska Native2114
Other1326
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboCariprazine 1-2 mgCariprazine 2-4.5 mgTotal
Hispanic or Latino14172253
Not Hispanic or Latino252256251759
Weight
Weight(kg)PlaceboCariprazine 1-2 mgCariprazine 2-4.5 mgTotal
Mean81.53 ± 16.1979.69 ± 16.3182.17 ± 17.3781.13 ± 16.65
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboCariprazine 1-2 mgCariprazine 2-4.5 mgTotal
Mean28.93 ± 5.0928.21 ± 5.5129.05 ± 5.5928.73 ± 5.41
Waist Circumference
Waist Circumference(cm)PlaceboCariprazine 1-2 mgCariprazine 2-4.5 mgTotal
Mean94.32 ± 13.4493.36 ± 14.2094.91 ± 14.6694.20 ± 14.12
08

Study locations

72 sites
  • Forest Investigative Site 077
    Garden Grove, California 92845, United States
  • Forest Investigative Site 019
    National City, California 91950, United States
  • Forest Investigative Site 039
    Oceanside, California 92056, United States
  • Forest Investigative Site 015
    Orange, California 92868, United States
  • Forest Investigative Site 050
    Orange, California 92868, United States
  • Forest Investigative Site 008
    Redlands, California 92374, United States
  • Forest Investigative Site 066
    Sherman Oaks, California 91403, United States
  • Forest Investigative Site 063
    Gainesville, Florida 32607, United States
  • Forest Investigative Site 029
    Jacksonville, Florida 32256, United States
  • Forest Investigative Site 012
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 023
    Miami, Florida 33183, United States
  • Forest Investigative Site 026
    Orlando, Florida 32806, United States
  • Forest Investigative Site 062
    Atlanta, Georgia 30328, United States
  • Forest Investigative Site 065
    Smyrna, Georgia 30080, United States
  • Forest Investigative Site 074
    Prairie Village, Kansas 66206, United States
  • Forest Investigative Site 040
    Flowood, Mississippi 39232, United States
  • Forest Investigative Site 068
    Creve Coeur, Missouri 63141, United States
  • Forest Investigative Site 061
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site 038
    Marlton, New Jersey 08053, United States
  • Forest Investigative Site 030
    Albuquerque, New Mexico 87106, United States
  • Forest Investigative Site 076
    Brooklyn, New York 11235, United States
  • Forest Investigative Site 037
    Mount Kisco, New York 10549, United States
  • Forest Investigative Site 067
    New York, New York 10021, United States
  • Forest Investigative Site 049
    New York, New York 10168, United States
  • Forest Investigative Site 047
    Canton, Ohio 44718, United States
  • Forest Investigative Site 021
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 022
    Portland, Oregon 97210, United States
  • Forest Investigative Site 027
    Salem, Oregon 97301, United States
  • Forest Investigative Site 069
    Bridgeville, Pennsylvania 15017, United States
  • Forest Investigative Site 025
    Philadelphia, Pennsylvania 19139, United States
  • Forest Investigative Site 031
    Reading, Pennsylvania 19604, United States
  • Forest Investigative Site 048
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 024
    Austin, Texas 78731, United States
  • Forest Investigative Site 020
    Dallas, Texas 75231, United States
  • Forest Investigative Site 070
    Houston, Texas 77054, United States
  • Forest Investigative Site 080
    San Antonio, Texas 78229, United States
  • Forest Investigative Site 028
    Salt Lake City, Utah 84106, United States
  • Forest Investigative Site 032
    Bellevue, Washington 98007, United States
  • Forest Investigative Site 034
    Kirkland, Washington 98033, United States
  • Forest Investigative Site 203
    Tallinn, 10614, Estonia
  • Forest Investigative Site 201
    Tallinn, 10617, Estonia
  • Forest Investigative Site 206
    Tallinn, 11615, Estonia
  • Forest Investigative Site 205
    Tallinn, 13517, Estonia
  • Forest Investigative Site 204
    Tartu, 50406, Estonia
  • Forest Investigative Site 208
    Tartu, 50417, Estonia
  • Forest Investigative Site 207
    Tartu, 51014, Estonia
  • Forest Investigative Site 202
    Võru, 65608, Estonia
  • Forest Investigative Site 301
    Helsinki, 100, Finland
  • Forest Investigative Site 302
    Helsinki, 100, Finland
  • Forest Investigative Site 304
    Helsinki, 100, Finland
  • Forest Investigative Site 303
    Helsinki, 40100, Finland
  • Forest Investigative Site 305
    Kuopio, 70110, Finland
  • Forest Investigative Site 308
    Oulu, 90100, Finland
  • Forest Investigative Site 307
    Pori, 28100, Finland
  • Forest Investigative Site 602
    Banska Stiavnica, 96901, Slovakia
  • Forest Investigative Site 603
    Bardejov, 08501, Slovakia
  • Forest Investigative Site 604
    Bratislava, 82007, Slovakia
  • Forest Investigative Site 606
    Bratislava, 85101, Slovakia
  • Forest Investigative Site 601
    Michalovce, 7101, Slovakia
  • Forest Investigative Site 605
    Rimavska Sobota, 97901, Slovakia
  • Forest Investigative Site 607
    Rimavska Sobota, 97912, Slovakia
  • Forest Investigative Site 803
    Lund, 22222, Sweden
  • Forest Investigative Site 802
    Malmö, 21152, Sweden
  • Forest Investigative Site 801
    Stockholm, 17145, Sweden
  • Forest Investigative Site 705
    Stepanivka, Kherson 73488, Ukraine
  • Forest Investigative Site 703
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site 704
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site 702
    Kyiv, 02660, Ukraine
  • Forest Investigative Site 701
    Kyiv, 04080, Ukraine
  • Forest Investigative Site 710
    Lugansk, 91045, Ukraine
  • Forest Investigative Site 709
    Odesa, 65014, Ukraine
  • Forest Investigative Site 706
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • Durgam S, Earley W, Guo H, Li D, Nemeth G, Laszlovszky I, Fava M, Montgomery SA. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016 Mar;77(3):371-8. doi: 10.4088/JCP.15m10070. PubMed 27046309 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Dec 2013, 23 months.

Results were first posted in May 2018, 4 years 4 months after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2011
First posted
Nov 10, 2011
StartActual
Dec 15, 2011
Primary completionActual
Dec 12, 2013
CompletionActual
Dec 12, 2013
Results first posted
May 1, 2018
Last update
May 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01469377
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Nov 10, 2011
Start date
Dec 15, 2011
Primary completion
Dec 12, 2013
Completion
Dec 12, 2013
Results posted
May 1, 2018
Last update
May 1, 2018

Study contacts

Willie Earley, MD
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion